Recombinant Human MAP2K1 Protein, His-tagged

• Cat.No.: MAP2K1-1035H
• Product Overview: Recombinant Human MAP2K1 Protein(Q02750-1)(M1-V393), fused with N-terminal His tag, was expressed in Sf9 insect cell.

Specification

• Source: Sf9 insect cell
• Species: Human
• Tag: N-His
• Protein length: M1-V393
• Form: 20 mM Hepes, 300 mM NaCl, 1 mM DTT, 0.05% Brij-35, 10% glycerol, pH 7.5.
• Bio-activity: The MAP2K1 activity was detected using Ultra Luminescence technology. The reaction was performed by incubating the MAP2K1 protein, ATP and substrate at 25°C for 60 min, then adding ADP-Glo reagent and reading RLU signal with BMG.
• Molecular Mass: 45.9 kDa
• Purity: >95% by SDS-PAGE
• Storage: Stable for 12 months upon stored at -80°C from the date of receipt. And avoid repeated freeze-thaws cycles.
• Concentration: 0.74 mg/mL by OD280
• Reconstitution: Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: MAP2K1 mitogen-activated protein kinase kinase 1 [ Homo sapiens ]
• Official Symbol: MAP2K1
• Synonyms: MAP2K1; mitogen-activated protein kinase kinase 1; PRKMK1; dual specificity mitogen-activated protein kinase kinase 1; MAPKK1; MEK1; MEK 1; MAPKK 1; MAPK/ERK kinase 1; MAP kinase kinase 1; ERK activator kinase 1; protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1); MKK1
• Gene ID: 5604
• mRNA Refseq: NM_002755
• Protein Refseq: NP_002746
• MIM: 176872
• UniProt ID: Q02750

Reviews

08/01/2020

The unmatched performance of the MAP2K1 protein in both ELISA assays and protein electron microscopy structure analysis showcases its versatility and reliability in various experimental settings.

05/18/2016

The MAP2K1 protein finds extensive utility in protein electron microscopy structure analysis.

04/11/2016

With its exceptional specificity and sensitivity, it enables precise and reliable detection of target molecules, making it a valuable tool in the field of diagnostic and research applications.

Q&As

Are there ongoing clinical trials targeting MAP2K1?

Yes, there are clinical trials exploring the efficacy and safety of MAP2K1 inhibitors in various cancers and other diseases.

Are there diagnostic tests specifically targeting MAP2K1 in clinical practice?

Some diagnostic tests may analyze MAP2K1 mutations, especially in the context of cancer, to inform treatment decisions.

What diagnostic applications does MAP2K1 have in cancer detection?

MAP2K1 mutations can serve as biomarkers in cancer diagnostics, aiding in the identification and classification of tumors.

How does MAP2K1 contribute to drug resistance in cancer treatment?

MAP2K1 mutations can be associated with resistance to certain cancer therapies, making it important to understand its role in treatment response.

Are there targeted therapies based on MAP2K1 in cancer treatment?

Yes, MAP2K1 inhibitors are being explored as targeted therapies in cancer treatment, aiming to block the abnormal signaling associated with MAP2K1 mutations.